NCT03739983
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have been receiving aromotase inhibitors (Ais) for at least 6 months prior to enrollment & plan to continue AIs for an additional 3 months
Exclusions: 
https://ClinicalTrials.gov/show/NCT03739983